Clene Inc.·4

Feb 20, 4:01 PM ET

Kiernan Matthew 4

4 · Clene Inc. · Filed Feb 20, 2026

Research Summary

AI-generated summary of this filing

Updated

Clene (CLNN) Director Matthew Kiernan Receives Option Award

What Happened Matthew Kiernan, a director of Clene Inc. (CLNN), was granted options for 2,755 shares of common stock on February 19, 2026. The grant was reported as a derivative acquisition with no cash paid at grant ($0.00 reported). Per the filing footnote, the options carry an exercise price of $4.73 per share and vest immediately upon grant.

Key Details

  • Transaction date: 2026-02-19 (reported on Form 4 filed 2026-02-20).
  • Transaction type: Award/grant of options (derivative); acquisition reported at $0.00.
  • Option terms noted: 2,755 share options, exercise price $4.73, immediate vesting (granted under Clene’s Amended 2020 Stock Plan).
  • Shares owned after transaction: not specified in the provided filing details.
  • Timeliness: Filed the next day (appears timely); no late filing indicated.

Context This was an option grant (a compensation award), not a stock purchase or sale. No shares were exercised or sold in this transaction — exercising later would require payment of the $4.73 per-share exercise price. Option grants to directors are commonly part of compensation and do not by themselves indicate buying or selling sentiment.

Insider Transaction Report

Form 4
Period: 2026-02-19
Transactions
  • Award

    stock option

    [F1]
    2026-02-19+2,7552,755 total
    Exercise: $4.73Exp: 2036-02-18common stock (2,755 underlying)
Footnotes (1)
  • [F1]This option was granted on February 19, 2026 as an option for 2,755 shares of Common Stock under the Clene Inc. Amended 2020 Stock Plan at an exercise price of $4.73 per share. The options vest immediately upon grant.
Signature
/s/ Jerome T. Miraglia POA|2026-02-20

Documents

1 file
  • 4
    rdgdoc.xmlPrimary

    FORM 4